Ras
As proteínas Ras são pequenas GTPases que atuam como interruptores moleculares na via de sinalização MAPK, controlando o crescimento, a diferenciação e a sobrevivência celular. Ras ativado inicia uma cascata de sinalização que inclui Raf, MEK e ERK, levando a várias respostas celulares. As mutações nos genes Ras são comuns em cânceres, tornando Ras um foco importante da pesquisa sobre o câncer. Na CymitQuimica, oferecemos uma variedade de moduladores de Ras para apoiar sua pesquisa em biologia do câncer, transdução de sinais e desenvolvimento terapêutico.
Foram encontrados 155 produtos de "Ras"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
ESI-08
CAS:<p>ESI-08 is an effective antagonist of EPAC2 with an IC50 of 8.4 μM. ESI-08 selectively blocks cAMP-induced EPAC activation but not cAMP-mediated PKA activation.</p>Fórmula:C20H23N3OSPureza:97.17%Cor e Forma:SolidPeso molecular:353.48KRAS inhibitor-6
CAS:<p>KRAS inhibitor-6 is a potent KRAS G12C inhibitor.</p>Fórmula:C27H30ClF2N5O3Pureza:98%Cor e Forma:SolidPeso molecular:546.01Methylophiopogonanone B
CAS:<p>1. Methylophiopogonanone B (MOPB) induces cell morphological change and Rho activation via melanocyte dendrite retraction and stress fiber formation.</p>Fórmula:C19H20O5Pureza:99.24% - 99.83%Cor e Forma:SolidPeso molecular:328.36MCP110
CAS:<p>MCP110 is an inhibitor of the interaction of Ras with Raf-1 and can be used in studies about the treatment of human tumors.</p>Fórmula:C33H36N2O3Pureza:97.23%Cor e Forma:OilPeso molecular:508.65BI-2852
CAS:<p>BI-2852: nanomolar affinity KRAS switch I/II pocket inhibitor; blocks signaling, halts KRAS mutant cell growth.</p>Fórmula:C31H28N6O2Pureza:98.98%Cor e Forma:SolidPeso molecular:516.59PROTAC KRAS G12C degrader-3
CAS:<p>PROTAC KRAS G12C Degrader-3 (Comp 283) serves as a potent degrader of KRAS G12C, utilized in cancer research [1].</p>Fórmula:C63H75ClN14O6Pureza:98%Cor e Forma:SolidPeso molecular:1159.81KRAS G12C inhibitor 58
CAS:<p>KRAS G12C inhibitor 58 is utilized in cancer research as an inhibitor of the KRAS G12C mutation [1].</p>Fórmula:C51H64ClF4N9O8SPureza:98%Cor e Forma:SolidPeso molecular:1074.62KRAS G12C inhibitor 5
CAS:<p>KRAS G12C inhibitor 5 is a KRas G12C inhibitor.</p>Fórmula:C32H37N7O2Pureza:98%Cor e Forma:SolidPeso molecular:551.68KRAS G12D modulator-1
CAS:<p>KRAS G12D modulator-1 (compound 6), a potent modulator of KRAS G12D, exhibits IC50 values ranging from 1-10 μM against NEA-G12D, PPI-G12D, and p ERK-AGS, and is</p>Fórmula:C30H36FN5O4Pureza:98%Cor e Forma:SolidPeso molecular:549.64Rac1-IN-3
CAS:<p>Rac1-IN-3 (Compound 2) is a Rac1 inhibitor exhibiting an inhibitory concentration 50 (IC50) of 46.1 μM [1].</p>Fórmula:C21H23N7O2Pureza:98%Cor e Forma:SolidPeso molecular:405.45TH-Z827
CAS:<p>TH-Z827 is a mutant-selective inhibitor targeting KRAS(G12D) with an IC50 of 2.4 μM, demonstrating specificity by not binding to KRAS(WT) or KRAS(G12C).</p>Fórmula:C30H38N6OPureza:98%Cor e Forma:SolidPeso molecular:498.66KRAS G12C inhibitor 32
CAS:<p>KRAS G12C Inhibitor 32, an eight-membered heterocyclic compound with nitrogen, acts as a potent inhibitor of KRAS G12C [1].</p>Fórmula:C29H30Cl3FN6O3Pureza:98%Cor e Forma:SolidPeso molecular:635.94SOS1/KRAS-IN-1
CAS:<p>SOS1/KRAS-IN-1 (Compound 2) serves as an inhibitor of SOS1/KRAS, with potential application in the study of diseases mediated by SOS1/KRAS [1].</p>Fórmula:C24H26F3N5OPureza:98%Cor e Forma:SolidPeso molecular:457.49pan-KRAS-IN-2
CAS:<p>Pan-KRAS-IN-2 (compound 6) is a broad-spectrum KRAS inhibitor exhibiting potent activity with IC50 values of ≤10 nM against KRAS wild type and its mutants (G12D</p>Fórmula:C34H34F2N4O3Pureza:98%Cor e Forma:SolidPeso molecular:584.66pan-KRAS-IN-3
CAS:<p>Pan-KRAS-IN-3 (Example 84) is a pan-KRAS inhibitor suitable for cancer research [1].</p>Fórmula:C33H32F3N5O2Pureza:98%Cor e Forma:SolidPeso molecular:587.63KRas G12C inhibitor 1
CAS:<p>KRas G12C inhibitor 1 is a compound that inhibits KRas G12C.</p>Fórmula:C31H38N6O3Pureza:98%Cor e Forma:SolidPeso molecular:542.67XRP44X
CAS:<p>XRP44X (XRP 44X) is a potent inhibitor of Ras-Net (Elk-3) pathway.</p>Fórmula:C21H21ClN4OPureza:99.67%Cor e Forma:SolidPeso molecular:380.87KRAS G12C inhibitor 59
CAS:<p>KRAS G12C Inhibitor 59 is a compound with anticancer properties.</p>Fórmula:C32H39F6N7O5Pureza:98%Cor e Forma:SolidPeso molecular:715.69RBC10
CAS:<p>RBC10 inhibits the binding of Ral to its effector RALBP1, as well as inhibiting Ral-mediated cell spreading of murine embryonic fibroblasts and anchorage-</p>Fórmula:C24H25ClN2O2Pureza:99.71%Cor e Forma:SolidPeso molecular:408.92KRAS G12C inhibitor 14
CAS:<p>KRAS G12C inhibitor 14 is a potent KRAS G12C inhibitor with an IC 50 of 18 nM [1].</p>Fórmula:C24H19ClF2N4O3Pureza:98%Cor e Forma:SolidPeso molecular:484.88KRAS G12C inhibitor 17
CAS:<p>KRAS G12C inhibitor 17 is a potent KRAS G12C inhibitor.</p>Fórmula:C24H20ClF2N3O3Pureza:98%Cor e Forma:SolidPeso molecular:471.88CCG-232964
CAS:<p>CCG-232964 is an orally active Rho/MRTF/SRF inhibitor that suppresses LPA-induced CTGF gene expression [1].</p>Fórmula:C15H15ClN2O3SPureza:98%Cor e Forma:SolidPeso molecular:338.81ML-099
CAS:ML-099 is a pan Ras-related GTPases activator that activates Rac1, Ras, GTP-binding protein (Rab7), Rab2A and cell division cycle 42.Fórmula:C14H13NO2SPureza:99.73%Cor e Forma:SolidPeso molecular:259.32KRAS G12C inhibitor 13
CAS:<p>KRAS G12C inhibitor 13 is a KRAS G12C inhibitor .</p>Fórmula:C40H46F3N7O4Pureza:98%Cor e Forma:SolidPeso molecular:745.83ARS-1323
CAS:<p>ARS-1323 is the racemate of ARS-1620 and a mutant K-ras G12C inhibitor.</p>Fórmula:C21H17ClF2N4O2Pureza:99.53%Cor e Forma:SolidPeso molecular:430.84pan-KRAS-IN-4
CAS:<p>Pan-KRAS-IN-4 (compound 5) is a potent KRAS inhibitor, demonstrating IC50 values of 0.37 nM for Kras G12C and 0.19 nM for Kras G12V [1].</p>Fórmula:C36H34F2N6O3Pureza:98%Cor e Forma:SolidPeso molecular:636.69BDP9066
CAS:<p>BDP9066 is a potent and selective MRCK inhibitor, inhibits MRCKβ and MRCKα/β, and can be used for the prevention and treatment of skin cancer.</p>Fórmula:C20H24N6Pureza:98.18%Cor e Forma:SolidPeso molecular:348.44Pan-RAS-IN-1
CAS:<p>Pan-RAS-IN-1 is an inhibitor of pan-Ras. It disrupts the interaction of Ras proteins and their effectors.</p>Fórmula:C36H41Cl2F3N6O2Pureza:99.77%Cor e Forma:SolidPeso molecular:717.65Rho GTPase inhibitor 1
CAS:<p>Rho GTPase inhibitor 1 (compound 7) is a potent inhibitor of Rho GTPase. It exhibits high affinity for Cdc42, Rac1, and RhoA, with dissociation constants (KDs) of 151 μM, 352 μM, and 232 μM, respectively. Additionally, Rho GTPase inhibitor 1 reduces cell migration in glioblastoma cell lines.</p>Fórmula:C18H16N2OCor e Forma:SolidPeso molecular:276.33SOS2 ligand 1
CAS:<p>SOS2 ligand 1 (compound 2) is a selective ligand for son of sevenless 2 (SOS2), exhibiting a KD value of 4.6 µM.</p>Fórmula:C19H21N5OCor e Forma:SolidPeso molecular:335.403(+)-Perillyl alcohol
CAS:<p>(+)-Perillyl alcohol (0.25-1 mM) inhibits cell growth in SW480 cells. At a concentration of 1 mM and a duration of 24 hours, (+)-Perillyl alcohol increases the number of cells in the G0/G1 phase and reduces the number in the S phase in SW480 cells.</p>Fórmula:C10H16OCor e Forma:SolidPeso molecular:152.23PAT-IN-1
CAS:<p>PAT-IN-1, a protein acyl transferases (PAT) inhibitor, competitively inhibits Erf2 autopalmitoylation (WO2017011518A1; compound 13) [1].</p>Fórmula:C45H68N4OCor e Forma:SolidPeso molecular:681.05KRAS G12C inhibitor 15
CAS:<p>KRAS G12C inhibitor 15 is a potent KRAS G12C inhibitor .</p>Fórmula:C25H21ClF2N4O3Pureza:98%Cor e Forma:SolidPeso molecular:498.91KRAS inhibitor-8
CAS:<p>KRAS inhibitor-8 is a potent KRAS G12C inhibitor.</p>Fórmula:C26H24ClF4N5O3Pureza:98%Cor e Forma:SolidPeso molecular:565.95KRAS G12D inhibitor 26
CAS:<p>KRAS G12D inhibitor 26 (Compound 64B) is an inhibitor of KRAS G12D with an IC50 ≤ 100 nM.</p>Fórmula:C35H44ClFN8O2Pureza:99.93%Cor e Forma:SolidPeso molecular:663.23INCB159020
CAS:<p>INCB159020 is an orally active inhibitor of KRAS G12D, exhibiting a KRAS G12D SPR value of 2.2 nM. It demonstrates anti-tumor activity.</p>Fórmula:C37H35ClFN7O2Cor e Forma:SolidPeso molecular:664.171pan-KRAS-IN-17
CAS:<p>pan-KRAS-IN-17 (Example 34) is an inhibitor that targets multiple forms of the KRAS protein.</p>Fórmula:C34H33F3N5O8PCor e Forma:SolidPeso molecular:727.623KRAS inhibitor-34
CAS:<p>KRAS inhibitor-34 (compound 27) is a KRAS inhibitor with an IC50 of 6.4 nM and is utilized in oncological research.</p>Fórmula:C43H41F3N6O3Cor e Forma:SolidPeso molecular:746.82SOF-436
CAS:<p>SOF-436 is a KRAS inhibitor that can suppress SOS1-mediated KRAS nucleotide exchange (IC50 = 60 μM) and inhibit the interaction between KRAS and the effector protein RAF. SOF-436 is applicable to cancer research.</p>Fórmula:C15H13F2NO4S2Cor e Forma:SolidPeso molecular:373.395J-104871
CAS:<p>J-104871 (UNII-6137X5QNJF) is an FTase inhibitor that inhibits tumor growth in nude mice transplanted with activated H-ras-transformed NIH3T3 cells.</p>Fórmula:C38H32N2O12Pureza:98%Cor e Forma:SolidPeso molecular:708.67RGT-018
CAS:<p>RGT-018 is a potent oral SOS1 inhibitor with antitumor properties. It exerts its anticancer activity by inhibiting KRAS activation, thereby hindering cancer cell proliferation.</p>Fórmula:C27H24F3N7O2Cor e Forma:SolidPeso molecular:535.52KRAS inhibitor-32
CAS:<p>KRAS inhibitor-32 (compound 139A) is a KRAS inhibitor utilized in cancer research.</p>Fórmula:C29H35FN10OS2Cor e Forma:SolidPeso molecular:622.78BMS-214662
CAS:<p>BMS-214662 is a selective farnesyl transferase inhibitor with anti-tumor activity, used in research on pancreatic cancer, head and neck cancer, and lung cancer.</p>Fórmula:C25H23N5O2S2Pureza:99.58% - 99.58%Cor e Forma:SolidPeso molecular:489.61pan-KRAS degrader 1
CAS:<p>Pan-KRAS degrader 1 (Compound 1) is a broad-spectrum KRAS degrader, exhibiting an inhibitory constant Ki value of 25 nM against KRASG12V as determined by surface plasmon resonance (SPR). Additionally, this compound demonstrates antitumor activity.</p>Fórmula:C22H26N8OSCor e Forma:SolidPeso molecular:450.56KRAS inhibitor-37
CAS:<p>KRAS inhibitor-37 (compound 2) is a potent inhibitor of KRAS, exhibiting low dissociation constants (KD) with various KRAS mutations: wild type (0.004 nM), G12D (0.041 nM), G12C (0.019 nM), and G12V (0.144 nM). This compound effectively inhibits cell proliferation, demonstrating half-maximal inhibitory concentrations (IC50) ranging from <2 nM to 14 nM in H358, SW620, and PANC08.13 cell lines. KRAS inhibitor-37 holds potential for cancer research applications.</p>Fórmula:C32H33ClFN7O3Cor e Forma:SolidPeso molecular:618.10KRas G12C inhibitor 2
CAS:<p>KRas G12C inhibitor 2 is a compound that inhibits KRas G12C.</p>Fórmula:C32H37N7O3Pureza:98%Cor e Forma:SolidPeso molecular:567.68Dorrigocin A
CAS:<p>Dorrigocin A, an analog of Migrastatin, inhibits the carboxymethyltransferase involved in Ras processing, reversing the morphology of Ras-transformed NIH/3T3 cells. Dorrigocin A holds potential for research as an anticancer and anti-arthritis agent.</p>Fórmula:C27H41NO8Cor e Forma:SolidPeso molecular:507.616ZCL279
CAS:<p>ZCL279 is a small molecule modulator (SMM) that inhibits the interaction between CDC42 and intersectin (ITSN). At lower concentrations (<10 μM), ZCL279 activates Cdc42, a cytoplasmic small GTPase in the Ras superfamily, while at higher concentrations (<10 μM) it significantly inhibits it.</p>Fórmula:C24H18N2O7S2Cor e Forma:SolidPeso molecular:510.539KRAS inhibitor-31
CAS:<p>KRAS inhibitor-31 (compound 33), a potent agent targeting KRAS, exhibits K D (SPR) values of 0.019 nM for KRas G12D, 0.019 nM for KRas G12C, and 0.096 nM for KRas G12V, illustrating its efficacy across these variants.</p>Fórmula:C33H30F3N5O4Cor e Forma:SolidPeso molecular:617.62XMU-MP-9
CAS:<p>XMU-MP-9, a bifunctional compound, targets the C2 domain of Nedd4-1 and the allosteric site of K-Ras. It enhances the interaction and induces conformational changes within the Nedd4-1/K-Ras complex. Furthermore, XMU-MP-9 facilitates the ubiquitination and degradation of various K-Ras mutants and inhibits the proliferation of cells with these mutants. This compound is useful in cancer research.</p>Fórmula:C19H13ClFN3OSCor e Forma:SolidPeso molecular:385.84AM-001
CAS:AM-001 is a non-competitive inhibitor of Epac1, preventing the activation of its downstream effector Rap1 in cultured cells. This compound is utilized in research related to cardiac diseases.Fórmula:C24H16FN3OS2Cor e Forma:SolidPeso molecular:445.53KRAS inhibitor-35
CAS:<p>KRAS inhibitor-35 (compound 72) is a KRAS inhibitor with an IC50 of 2 nM, utilized in tumor research.</p>Fórmula:C38H32F4N6O3SCor e Forma:SolidPeso molecular:728.76KRAS inhibitor-41
CAS:<p>KRAS inhibitor-41 is a KRAS inhibitor with an IC50 value of less than 0.01 μM for both KRAS G12D and KRAS G12V mutations. It effectively inhibits RAS mutant cell lines GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS inhibitor-41 is applicable for cancer research.</p>Fórmula:C30H37FN10OSCor e Forma:SolidPeso molecular:604.745Sosimerasib
CAS:<p>Sosimerasib is an inhibitor of the kirsten rat sarcoma viral oncogene homolog (KRAS) and exhibits antitumor activity.</p>Fórmula:C36H39ClFN7O4Cor e Forma:SolidPeso molecular:688.191KRAS G12D inhibitor 28
CAS:<p>KRAS G12D inhibitor 28 (Compound 1) is an inhibitor of KRAS G12D and can be utilized in cancer research.</p>Fórmula:C35H32Cl2FN5OCor e Forma:SolidPeso molecular:628.57
